MetaCap

REGENXBIO (RGNX) vs Tevogen (TVGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

REGENXBIO (RGNX) has outperformed Tevogen (TVGN) over the past year, losing 39.3% versus a loss of 73.8%. REGENXBIO is the larger company by market cap ($473.4 million vs $405.2 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RGNX-39.32%TVGN-73.84%
+41%-24%-89%
Nov 21, 20251 yearNov 20, 2026
RGNX-75.45%TVGN-98.81%
+26%-40%-105%
Jan 3, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RGNX versus TVGN key metrics
MetricRGNXTVGN
Share price$7.16$5.90
Market cap$473.44M$405.20M
1-day change-0.28%-6.35%
YTD return-50.28%-64.35%
1-year return-39.32%-73.84%
5-year return-76.87%—
EPS (TTM)$-3.20$-7.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$170.44M—
Revenue growth (YoY)+104.54%—
Net income (latest FY)$-193.88M$-26.28M
Operating margin-94.58%—
Net margin-113.75%—
52-week high$16.19$24.90
52-week low$5.46$3.64
Distance from 52-week high-55.78%-76.31%
Analyst consensusstrong_buy—
Avg. price target upside+198.88%—
Average volume1.39M7.94K
Shares outstanding66.12M68.68M
Employees37118
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RGNX has outperformed TVGN by 34.5 percentage points over the past year.

About REGENXBIO

RGNX stock →

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees

About Tevogen

TVGN stock →

Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

RGNX vs TVGN FAQ

Which is bigger, REGENXBIO or Tevogen?

REGENXBIO (RGNX) is larger, with a market capitalization of $473.44M compared with $405.20M for Tevogen (TVGN).

Which stock has performed better over the past year, RGNX or TVGN?

RGNX returned -39.32% over the past 12 months, compared with -73.84% for TVGN (price return, excluding dividends). Past performance does not predict future results.

Are REGENXBIO and Tevogen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons